Newspaper adverts, billboards, facebook updates its all...

Newspaper adverts, billboards, facebook updates its all happening, or is it? We are still waiting to find out the record date that the company said it expected to be in August for the rights issue and placement to sophisticated investors.

Nice pictures on the website show production, but we still do not know the quantities that have been produced. Many questions still need to be answered and the time is ticking away.

Words like licensing agreements and international markets are starting to appear in the companies announcements . Wading through the companies annual reports for the last few years they have stated their focus was shifted of tripeptofen, and into re establishing ThermaLIFE into the Australian market, and then international markets, namely UK, USA and Asia.

I can see the tie up in USA with our holding in MPLH an OTC company, which in its latest filings with the SEC had some terminology adjusted to allow the sale and marketing of ThermaLIFE, whereas previously it was prohibited to do so.
The company has also stated in its reports affiliations with companies and large pharmas in Asia and UK.
So now with thermaLIFE marketed in Australia, it could now pave the way for international expansion as the next logical step for the company.

Let me hypothetically put something forward.

The company will need to dangle some big carrots for the CR and rights issue to be a success. So maybe in the prospectus they could announce they are "negotiating" a license deal for overseas markets, which could give the company an upfront payment and ongoing royalties per tube sold.

If this were the case , it would free up the company to finalise the next 2 products RED & Savantac,which the company has stated most regulatory hurdles have been met with thermaLIFE, as these are derivative products. at the same time income is coming in. They get released into Australia and then to the licensed partners, and the company has income from 3 products , plus royalties. With this solid foundation pharmanet can then concentrate on Tripeptofen.

Hypothetical scenario and maybe far fetched but ,in the announcement re CR Cunninghams are being paid in options, so maybe they are of the opinion they will make more money that way?

If they make money it means all shareholders will.